Eye laser technology reimagined.
Experience femto-level precision in a compact, pico-green laser system built for the eye—starting with glaucoma.
Glaucoma is the leading cause of irreversible blindness worldwide. Today, more than 181 million people live with glaucoma or ocular hypertension—and that number is growing.
Most patients begin with daily medications, but adherence drops quickly; nearly half stop taking drops within the first year. For those needing more advanced care, current procedures can be invasive, complex, or costly.
Meanwhile, treatment patterns are shifting: globally, laser procedures are performed four times more often than glaucoma surgeries. The demand for accessible, safer, simpler, and more effective options has never been greater.
Introducing SoftLase™
SoftLase is a new kind of laser platform designed to be non-invasive, safe, effective, compact, and accessible to everyday practices. By putting patient comfort first, treatments are quick, gentle, and require minimal recovery.
The system reduces complexity while delivering highly efficient treatments with flexible options. By being cost-effective, SoftLase makes glaucoma care more accessible to patients everywhere.
Reimagining Glaucoma Care with Three Breakthrough Treatments
PicoLumen™
Creates a small outflow channel in under a second using low energy, enabling precise fluid regulation.
ThinMesh™
Removes a thin portion of the trabecular meshwork while preserving underlying layers — reducing outflow resistance by targeted thinning.
SoftMesh™
Gently opens the trabecular cell structure to create micro holes and revitalize natural outflow while maintaining the overall integrity of the tissue.
The Team
Christopher Horvath, PhD
Chief Executive Officer
Christopher Horvath, PhD is a laser physicist, technology innovator, and entrepreneur dedicated to solving complex challenges through practical innovation. With more than 100 patents, he began his ophthalmic career over 30 years ago by inventing and developing the first femtosecond laser for ophthalmology, successfully commercialized as the IntraLase® femtosecond laser system.
He went on to help shape modern ophthalmic laser technology with the PurePoint® (Alcon) retina laser and the KeLoTec™ femtosecond cataract system, later expanding into glaucoma with the design and development of the XEN® Gel Stent. As Founder and CEO of EyeX Solutions, Dr. Horvath leads the company’s technology and vision to deliver advanced laser platforms for the entire eye—beginning with breakthrough innovations in glaucoma treatment.
Prof. Herbert A. Reitsamer, MD
Prof. Herbert A. Reitsamer, MD, is Chairman of the Department of Ophthalmology and Director of Experimental Ophthalmology & Glaucoma Research at SALK/Paracelsus Medical University in Salzburg, Austria. An ophthalmologist, physiologist, and electrotechnical engineer by training, he is an internationally recognized expert in glaucoma and anterior segment surgery. His research has focused on aqueous dynamics, minimally invasive glaucoma surgery, experimental therapies, and clinical outcomes. Prof. Reitsamer is widely regarded for integrating clinical practice, research, and education, and for his leadership in advancing innovative treatment concepts that translate scientific discovery into improved patient care.
Medical Advisory Board
Ike Ahmed, MD
Toronto, Canada
Analisa Arosemena, MD
Miami, USA
Ian Pitha, MD
Salt Lake City, USA
Arsham Sheybani, MD
St. Louis, USA
